'Low-cost Carboplatin boosts survival in aggressive breast cancer'

Women 50 years and below to benefit most from new TMC study

geetanjali

Geetanjali Minhas | October 25, 2025 | Mumbai


#Cancer   #Health   #Healthcare  
Dr. Sudeep Gupta (left) and Dr. Rajendra A. Badwe briefing the media in Mumbai on Friday (GN Photo)
Dr. Sudeep Gupta (left) and Dr. Rajendra A. Badwe briefing the media in Mumbai on Friday (GN Photo)

Adding the inexpensive chemotherapy drug Carboplatin to standard treatment significantly improves survival in patients with triple-negative breast cancer (TNBC), a clinical trial at the Tata Memorial Centre (TMC) in Mumbai has found.

TNBC is an aggressive form of breast cancer and lacks the common hormone and protein markers seen in other breast cancers, leaving chemotherapy as one of the few effective treatment options.

The  randomized Phase III trial was held over a 10-year period (2010-20) on 720 Indian women with Stage II–III TNBC. It was funded by the Department of Atomic Energy, Government of India.

All participants received the standard chemotherapy regimen (weekly paclitaxel followed by doxorubicin plus cyclophosphamide every 21 days for 4 cycles) to shrink their tumours before surgery.  Half the patients also received weekly Carboplatin injections for eight weeks before surgery.

Carboplatin is a commonly available inexpensive chemotherapy drug often used for other cancers. It’s a cost-effective option for resource-limited countries where TNBC represents nearly 30% of breast cancers. All patients later underwent surgery, radiation, and long-term follow-up.

The total cost of carboplatin for the entire eight-week treatment is approximately between Rs 5,000 and Rs 6,000, ranging from Rs 625 to Rs 750 per dose every week. The total cost of drugs for the eight-week treatment and chemotherapy comes up to around Rs 25,000.

Key Findings
After an average follow-up of 67 months, the Carboplatin group improved  in overall survival (5 years) from 66.8% to 74.4% with 7 more women out of every 100 alive at five  years after Carboplatin treatment. Disease-Free Survival (5 years) improved from 64% to 71%.The improvement was dramatic in premenopausal women aged 50 years and below with overall survival improving from 66% to 77% and disease-free survival improving  from 62% to 74%.

The addition of carboplatin caused no major increase in side effects due to its weekly low-dose schedule.

“This landmark Indian trail settles a long standing question on breast cancer treatment. We now have evidence that a simple, affordable addition to chemotherapy can save lives. Carboplatin increased the five-year survival rate by around 7.6 percentage points -  a statistically and clinically meaningful improvement,” said Dr. Sudeep Gupta, Professor of Medical Oncology and Director, Tata Memorial Centre and lead author of the study, during a media briefing here on Friday.

Dr. Rajendra A. Badwe, Honorary Professor Emeritus, Ex-Director, TMC and principal investigator of the study  said that every year 1.8 lakh women in India are afflicted with breast cancer. Every year  Tata Memorial Hospital in Mumbai gets 5000 new breast cancer patients and 30% of these patients  are high mortality triple negative. This study has been hailed by global cancer specialists calling it  ‘practise defining’. It shows high-quality research in India can change global cancer care.

The study was earlier presented at the San Antonio Breast Cancer Symposium in 2022.

Comments

 

Other News

Maharashtra FDA cracks down on `health supplements`; seizes stock worth Rs 1.39 cr

The Maharashtra Food and Drug Administration (FDA) has issued a comprehensive state wide compliance order tightening regulations governing health supplements, nutraceuticals, sports nutrition products and foods for special dietary and medical purposes. The order, issued by Commissioner of Food Safety, Tu

States face rising fiscal pressure as spending outpaces revenue

States across India are facing increasing fiscal pressures, with revenue expenditure growing faster than revenue receipts since 2022-23, largely driven by rising subsidies and transfers, according to the annual ‘State of State Finances 2026-27’ report released by PRS Legislative Research.

Global value chains and sustainability

When a country’s factories become part of global supply chains, making parts or products that feed into goods sold around the world, the economy usually looks stronger. Output rises, exports grow, and technology improves. But the research behind this article [Bhayana and Nag, 2026] asks a harder qu

Narrative sovereignty in the digital age

In today’s world, competition between countries is not limited to military strength or economic power. It also takes place through the stories countries tell about themselves and the way others describe them. Social media and digital platforms have made this competition faster and more visible. Whe

The hidden cost of voter-ID link with welfare

On October 30, panchayati raj minister Rajiv Ranjan Singh, better known as Lalan Singh, told a national workshop in Delhi that Aadhaar would no longer be the basis for government schemes. His argument seemed simple enough. Aadhaar centres are now in every locality, and anyone can get a card made for anyb

The silent epidemic in the Northeast

In Mizoram, more than nine in ten people can read. Anyone there can find out how HIV spreads and how to protect themselves. Yet Mizoram has the highest rates of HIV patients in the country. If education were enough, this would’ve been solved long ago, but it was not. The answer tells us something a

Upcoming Conferences



-->

Archives

Current Issue

Opinion

Facebook Twitter Google Plus Linkedin Subscribe Newsletter

Twitter